Given the lack of cost-effectiveness studies of PD-L1 inhibitors for first-line treatment of NSCLC patients with high PD-L1 expression, as well as the scarcity of recommended therapeutic alternatives in this type of patients, this pharmacoeconomic analysis and the results obtained are of particular interest and importance. The gene discussed is CD274; the disease is non-small cell lung carcinoma.